Related Experiment Videos
The maturation of differentiation therapy
The New England Journal of Medicine
|August 6, 1992
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).
Annals of oncology : official journal of the European Society for Medical Oncology·2017
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
Annals of oncology : official journal of the European Society for Medical Oncology·2017
Current Status of U.S. Clinical Trials in Chronic Lymphocytic Leukemia.
Leukemia & lymphoma·2016
How we manage follicular lymphoma.
Leukemia·2014
Fibromyalgia.
The New England journal of medicine·2026
Health Care-Associated Infections in U.S. Hospitals, 2023 versus 2015.
The New England journal of medicine·2026
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
The New England journal of medicine·2026
Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.
The New England journal of medicine·2026
Andes Virus - A Clinical Review.
The New England journal of medicine·2026
Platelet-Activating Anti-Platelet Factor 4 Disorders.
The New England journal of medicine·2026
Development of a Novel, Eco-Friendly Mechanical Cell Lysis Process Using Hollow Fiber Filter for AAV Manufacturing.
Biotechnology and bioengineering·2026
Programmed repair of disease-causing UGA premature termination codons in mammalian brain.
Nucleic acids research·2026
Molecular profiling and functional analyses of umbilical cord mesenchymal stem cell-derived extracellular vesicles for dry eye diseases.
Extracellular vesicles and circulating nucleic acids·2026
Immunotherapy for tuberculosis: current landscape, mechanistic insights, and translational perspectives.
Frontiers in immunology·2026
Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis After Failure of Ustekinumab: A Multicenter Retrospective Study.
The Journal of clinical and aesthetic dermatology·2026